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1. Introduction  
Osteoporosis is a chronic bone disease, caused by an imbalance between bone resorption 
and bone formation (Riggs & Melton, 1986), in which the skeleton becomes fragile and leads 
to an increased risk of fractures. In osteoporosis the bone mineral density is rapidly reduced, 
the bone microarchitecture is disrupted and the amount/variety of non-collagenous bone 
proteins is altered (Chestnut, 1995; Paschalis et al., 1997). In menopausal women, the rapid 
decrease of estrogens is the predominant cause of the imbalance between bone formation 
and bone resorption that results, in turn, in severe bone loss (Riggs & Melton, 1986).  
Hormone Replacement Therapy (HRT), based on estrogen administration, is a method to 
recover both bone loss and incidence of skeletal fractures in postmenopausal women 
(Turner et al., 1994); however, as it is well known, it increases, as negative side effects, the 
occurrence of cardiovascular diseases and endometrial/breast/ovarian malignant cancers 
(Beral, 2003; Genant et al., 1998; Lacey et al., 2002; Termine & Wong, 1998). In addition to 
HRT, other compounds such as bisphosphonates, calcitonin, calcium products, RANK 
Ligand, stronzium ranelate, PTH 1-34, thiazide diuretics and ipriflavone (Bruhn, 2010; El-
Desoky et al., 2009; Lacroix, 2000; Rybchyn et al., 2011; Schoofs, 2003; Wasnich, 1983; Zhang 
et al., 2010) are currently used as pharmacological approaches to osteoporosis, but they are 
often associated with negative side effects. Therefore, the need to find safer and more 
effective bone protective agents is still prominent. A great number of preparations from 
medicinal plants was shown to reduce bone loss induced by ovariectomy in rats (Occhiuto 
et al., 2007) and to increase bone density in postmenopausal women (Clifton-Bligh, 2001). 
Among natural products increasingly used as an alternative therapy, the phytoestrogenic 
isoflavones have been shown to increase bone density in postmenopausal women following 
high dietary intake (Mei et al., 2001). Also in animal studies, the administration of 
isoflavones or their derivatives prevented bone loss in ovariectomized rats. They are 
structurally similar to estradiol and their estrogenic-like activity may also depend on their 
affinity for some estrogen receptors (ERs). Phytoestrogens appear to bind preferentially to 
the ERǃ and have been classified as Selective Estrogen Receptor Modulators (SERMs) (An et al., 
al., 2001; Brzezinski & Debi, 1999; Messina et al., 2006). ERǃ may play a protective role in breast 
breast cancer development by reducing mammary cell growth, as well as inhibiting the 
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stimulatory effects of ERǂ (An et al., 2001; Strom et al., 2004). Considering the properties of such 
such natural compounds, phytoestrogens could be employed as Complementary/Alternative 
Medicine (CAM) instead of HRT, in order to recover menopausal symptoms (Lee et al., 2000; 
Morris et al., 2000; Morris et al., 2006). Such evidence that SERMs mime estrogens as 
osteoprotective substances (Albertazzi, 2002; Wang et al., 2006) without displaying the 
negative side effects on the etiogenesis of some types of cancer (Duffy et al., 2007; Eason et 
al., 2005; Gallo et al., 2006; Garcia-Perez et al., 2006; Lian et al., 2001; Limer & Speirs, 2004; 
Murray et al., 2003; Wu et al., 2002) suggests interesting perspectives in planning alternative 
treatment strategies. 
A great number of preparations from medicinal plants, including red clover, hops and black 
cohosh, have been tested to investigate their influence on ovariectomy-induced bone loss. 
Red clover (Trifolium pratense L.) was shown to reduce bone loss induced by ovariectomy in 
rats (Occhiuto et al., 2007) and to increase bone density in postmenopausal women (Clifton-
Bligh, 2001). The prenylated flavanone contained in hops (Humulus lupulus L.), 8-
prenylnaringenin (8-PN), and genistein (found in a number of plants including lupin, fava 
beans, soybeans, kudzu, and psoralea) seem to protect from ovariectomy-induced bone loss 
in rats, while exhibiting minimal trophic effects on uterus endometrium (Garcìa-Pérez et al., 
2006; Hümpel et al., 2005); in particular isoflavone genistein, by enhancing uterine 
endometrial glandular apoptosis in vivo and in vitro, may confer protection against uterine 
carcinoma (Eason et al., 2005). Moreover, a reduced bone resorption was demonstrated also 
after black cohosh (Cimicifuga racemosa L.) therapy and it was ascribed to the significant 
binding of its components to estrogen receptors (Wuttke et al., 2003). Despite the huge 
amount of data published in vitro and in vivo on another phytoestrogen, Ferutinin, extracted 
from Ferula hermonis root (Fig. 1) (Abourashed  et al., 2001), whose effect was investigated on 
calcium-related cellular processes, few observations are reported in literature concerning 
ferutinin role on the skeleton, particularly on bone metabolism in both the preventing and 
curative treatment of osteoporosis. Ferutinin shows high affinity for both subtypes of 
estrogen receptors (ERs ). Even if ferutinin can bind to both ERs, it acts as an agonist for ERǂ 
and as agonist/antagonist for ERǃ (Ikeda et al., 2002). Thus, this compound may be useful as 
a selective estrogen receptor modulator (SERM) (Appendino  et al., 2002). 
Recently, the interest of the authors was to investigate the effects of ferutinin administration 
on bone metabolism in prevention and in recovery of severe estrogen deficiency-
osteoporosis and to compare them with those of estradiol benzoate treatment, in order to 
propose an alternative solution to the hormone replacement therapy (HRT) commonly used 
in osteoporotic women. The animal model used, i.e. ovariectomized rat, appears to be an 
appropriate model for collecting information which could be applied to human 
postmenopausal osteoporosis, because of the many similarities of the pathophysiological 
mechanisms (Comelekoglu et al., 2006; Kalu, 1991; Wronski & Yen, 1991). 
Further crucial problem correlated to the use of  the phytoestrogen ferutinin is to evaluate 
its side effects, specifically on the organs which are reputed to be the target of estrogen 
effects, like uterus, vagina, mammary glands. It is well-known that estrogens stimulate 
endometrial proliferation and their administration in HRT was associated to an increased 
risk of cancer. Some phytoestrogens are claimed to have beneficial effects with a minor 
incidence of undesired side effects in comparison with estrogen therapy. Proliferative 
activity in estrogen-responsive cells can be either enhanced or suppressed by 
phytoestrogens depending on their concentration and relative potency (Whitten & Patisaul, 
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2001). Clinical reports about phytoestrogen effect on endometrial cancer are limited to case-
controlled observational studies (Johnson et al., 2001). Hence the interest of the authors also 
in the problem of ferutinin side effects. 
 
 
Fig. 1. Ferula Hermonis. 
2. Methods 
The authors report the following methods from some animal experiments they performed in 
the recent past on the topic.  
2.1 Experimental animals and treatments 
For animal experiments female Sprague-Dawley rats, aged 7 weeks and weighing 170-190 g 
at the beginning of the experiments, were used, according to the general age-models 
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reported in literature (Fanti et al.,1998; Kalu, 1991). They were housed two per cage and 
maintained in standard conditions with a 12:12 light/dark cycle, at the temperature of 22 ± 
1°C and 55-60% relative humidity. Commercial rat pellets free of estrogenic substances and 
drinking water were available ad libitum. After a 7-day adaptation period, the animals were 
randomly divided in different groups according to two protocols (for prevention and 
recovery of bone loss, respectively). Animal care, maintenance and surgery were conducted 
in accordance with the Italian law (D.L. n. 116/1992) and European legislation (EEC n. 
86/609). The experimental designs and procedures received the approval of the Bioethical 
Committee of the Italian National Institute of Health.  
2.1.1 Preventing study protocol 
The animals were randomly divided in four groups (Palumbo et al., 2009). Rats of group 1 
were sham-operated, while rats of other groups were bilaterally ovariectomized (OVX) under 
ketamine hydrochloride plus xylazine hydrochloride anaesthesia and the ovaries were 
bilaterally removed; sham-operation was performed in the same way as ovariectomy, but only 
exposing the ovaries. Starting on the day after the ovariectomy, half of the female rats were 
submitted to the following treatments for 30 days and the remaining half for 60 days: 
Group 1 (SHAM): Sham-operated controls receiving vehicle (5% Tween 80  in water) 
Group 2 (C-OVX): Ovariectomized controls receiving vehicle (5% Tween 80 in water) 
Group 3 (F-OVX): Ovariectomized treated with ferutinin 2 mg/kg/day 
Group 4 (EB-OVX):  Ovariectomized treated with estradiol benzoate 1.5 μg/rat twice a week.  
Ferutinin, whose formula is showed in Figure 2, was solubilized in Tween 80 (5%) and 
deionized water and administered in the volume of 5 ml/kg by oral gavage (per os). The 
dosage was chosen taking into account previous studies on rat sexual behavior (Zanoli et al., 
2005; Zavatti et al., 2006). Control animals (groups 1 and 2) received the same volume of 
vehicle solution. Estradiol benzoate, used as a reference compound, was dissolved in peanut 
oil and subcutaneously injected in the volume of 0.3 ml/rat. 
 
H
O
O
OH
OH
 
Fig. 2. Chemical structure of ferutinin. 
The body weights of all animals were recorded before ovariectomy and after 30 and 60 days 
of treatment. Half of each rat group was sacrificed after 30 days of treatment and the 
remaining animals at the end of the experiment. 
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2.1.2 Recovering study protocol 
The rats was randomized into four groups (Ferretti el al., 2010). One group of rats were 
sham operated, while the rats of the other three groups were ovariectomized. Ovariectomy 
and sham-operation were performed as above described in the protocol for preventing 
study. Two months after ovariectomy, namely when osteoporosis was obtained by the 
consequent estrogen deficiency, half of the rats of each  group underwent the following 
treatments for 30 days and the remaining ones for 60 days:  
Group 1 (SHAM): Sham-operated controls receiving vehicle (5% Tween 80 in water) 
Group 2 (C-OVX): Ovariectomized controls receiving vehicle (5% Tween 80 in water) 
Group 3 (F-OVX): Ovariectomized treated with ferutinin 2 mg/kg/day  
Group 4 (EB-OVX): Ovariectomized treated with estradiol benzoate 1.5 μg/rat twice a week. 
Ferutinin and  Estradiol benzoate were used as above described.  
The body weight of each animal was recorded at 4 different times: before ovariectomy (i.e., 
at the start of the experiment), two months after ovariectomy (namely, at the beginning of 
treatment), and after 30 and 60 days of treatment. At the end of the treatments, all rats were 
sacrificed. 
2.2 Histology and histomorphometrical evaluation  
Soon after the sacrifice, the 4th, 5th lumbar vertebrae and the right femurs were removed, 
processed and embedded in methyl methacrylate according to standard protocol for light 
microscopy. Serial sections of 200μm thickness were taken from both lumbar vertebrae and 
femurs by means of a diamond-saw microtome cutting system. In particular, the 4th lumbar 
vertebrae were cut according to sagittal planes, whereas the 5th lumbar vertebrae were 
transversely cut; concerning the femurs, the distal epiphyseal level was sagittally sectioned, 
whereas the shaft was transversely sectioned at the mid-diaphyseal level (Fig. 3). 
Histomorphometric analysis was performed on Fast-Green or Alizarin-Red stained sections 
using a light microscope equipped with an image analysis system. In histomorphometric 
evaluations of vertebral bodies, only trabecular bone was taken into account: it was 
manually selected, outlining the internal surface of the cortical bone (Fig. 3A,B). In femoral 
sagittal sections, a constant area (3.5mm2) of trabecular bone was defined by drawing a 
circular line adjacent to the cartilagineous plate (Fig. 3C). In transversal mid-diaphyseal 
femoral sections the cortical bone area was measured (Fig. 3D). 
The following parameters were calculated: 
 the ratio between the trabecular bone  area (BV) and the total area (TV), i.e. the trabecular 
bone volume (BV/TV) expressed in percent values, in trabecular bone; 
 the difference between the total cross section area and the medullary canal area , i.e. the 
cortical bone area (Ct-B-Ar), in cortical bone.  
Only in preventing study protocol, in order to obtain a more precise evaluation of the 
collected data (i.e. to eliminate the effects of body weight on bone histomorphometric 
parameters), both the ratio BV/TV and the value Ct-B-Ar were “normalized” (i.e. corrected) 
with respect to body weight (dividing the calculated parameters by the body weight) on the 
basis that ovariectomy implies a considerable weight increase, while the chronic treatment 
with both ferutinin and estradiol benzoate (starting the day after ovariectomy) avoids such 
increment. On the contrary, in recovering study protocol the same treatment was performed 
2 months after ovariectomy and after such period, the body weights of all OVX animals (C-
OVX, F-OVX, EB-OVX) were all similar; for this reason, histomorphometric parameters (BV 
⁄TV and Ct-B-Ar) were not normalized with respect to body weight.  
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Fig. 3. Histological sections taken from SHAM group in which the histomorphometrical 
analyses were performed. (A) sagittal section of 4th lumbar vertebra; (B) transversal section 
of 5th lumbar vertebra; (C) sagittal section of the distal epiphyseal level of femur; (D) 
transversal section at the mid-diaphyseal level of femur. The dotted lines indicate the areas 
in which evaluations were recorded. (Figure by Palumbo et al., 2009).  
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2.3 Biochemical assays 
Blood samples from experimental rats were collected in tubes and the serum was immediately 
separated by centrifugation, aliquoted into small volumes and stored at –20°C for analysis. The 
serum levels of magnesium, calcium, inorganic phosphorus and alkaline phosphatase (ALP) 
activity were determined by colorimetry using commercially available test kits. 
2.4 Statistical analysis 
One-way analysis of variance (ANOVA) with Newman-Keuls test for post-hoc 
comparisons between individual treatment groups and controls was performed. Student’s 
t-test was used where appropriate. Values of P<0.05 indicate significant differences 
between groups. 
3. Results 
3.1 Body weights 
Both in preventive and recovering studies, initial body weights of the four animal groups 
were similar.  
In preventing study (Table 1), as expected, the body weight of C-OVX rats, sacrificed at 30 
and 60 days after ovariectomy, was significantly higher than that of SHAM animals. The 
chronic administration of ferutinin as well as estradiol benzoate significantly 
counterbalanced body weight increase. It must be stressed that estradiol benzoate (EB) 
treatment was able to equal the body mass gain of sham-operated control rats, while 
ferutinin caused a more marked decrease in body weight in comparison to EB.  
 
 
TABLE 1 -  Body weight in Preventing study  
Treatment group Initial BW BW at 30th day BW at 60th day 
SHAM 198.9±2.4 249.7±4.1 246.0±5.4 
C-OVX 205.1±2.1 308.4±5.6a 335.2±9.8a 
F-OVX 196.8±1.7 194.4±4.0b,c 246.0±5.4 
EB-OVX 204.7±3.1 229.8±1.9b 246.8±3.4b 
Table 1. Effect of ferutinin and  estradiol benzoate on body weight of ovariectomized rats. 
Values represent mean±SEM. Anova followed by Newman-Keuls post test: aP<0.001 vs. 
SHAM, bP<0.001 vs. C-OVX, cP<0.001 vs. EB-OVX. SHAM: sham-operated  controls 
receiving vehicle; C-OVX: ovariectomized controls  receiving vehicle; F-OVX: 
ovariectomized treated with ferutinin; EB-OVX: ovariectomized treated with estradiol 
benzoate; BW: body weight. 
In recovering study (Fig. 4) two months after ovariectomy (namely, at the beginning of 
treatment) the body weight of ovariectomized rats (C-OVX, F-OVX and EB-OVX) was 
significantly higher, as expected, with respect to SHAM, but after both 30 and 60 days of 
chronic administration of ferutinin as well as of estradiol benzoate the body weight reduces 
significantly in comparison to C-OVX and it is similar to that of SHAM one. 
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Fig. 4. Recovering study.  Histograms showing the mean values of body weights-BW (g) 
recorded from all animal groups at 4 different times: (1) at the start of the experiment (before 
ovariectomy), (2) two months after ovariectomy, (3) after 30 days of treatment and (4) after 
60 days of treatment. Values are expressed as mean  SEM. ***P<0.001 vs. C-OVX; P<0.001 
vs. SHAM (Anova followed by Newman-Keuls test). SHAM: sham-operated controls 
receiving vehicle; C-OVX: ovariectomized controls receiving vehicle; F-OVX: 
ovariectomized treated with ferutinin; EB-OVX: ovariectomized treated with estradiol 
benzoate; BW: body weight. 
3.2 Histology and histomorphometric analysis 
3.2.1 Bone mass in preventing study protocol 
Histological observations of bone sections of vertebrae and femurs from treated and control 
animal groups underlined, as it is expected, that bone mass is clearly lower in C-OVX rats, 
with respect to SHAM and treated (F-OVX and EB-OVX) animals (Fig. 5).  
The histomorphometric results obtained after 30 and 60 days of treatment showed that 
ovariectomy induced reduction in bone mass of lumbar vertebrae and femur, which is not 
observed in the animals treated with ferutinin or estradiol benzoate (Figs. 6 and 7); in 
particular, comparing the two groups of ovariectomized animals treated with ferutinin (F-
OVX) and estradiol benzoate (EB-OVX), the mean values are always higher in F-OVX with 
respect to EB-OVX, sometimes displaying statistical significance. 
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Fig. 5. Preventing study. LM micrographs showing the bone histology from the four 
experimental animal groups: (A) sagittal sections of 4th  lumbar vertebra; (B) transversal 
sections of 5th lumbar vertebra; (C) sagittal sections of the distal epiphyseal level of femur; (D) 
transversal sections at the mid-diaphyseal level of femur. (Figure by Palumbo et al., 2009). 
www.intechopen.com
 
Osteoporosis 
 
720 
 
 
 
Fig. 6. Preventing study. Mean values of histomorphometric normalized parameters, expressed 
as BV/TV (%/g) and CT-B-Ar (mm2/g), in both trabecular and cortical bone of the four animal 
groups, after 30 days from ovariectomy. (A) sagittal sections of 4th  lumbar vertebra; (B) 
transversal sections of 5th lumbar vertebra; (C) sagittal sections of the distal epiphyseal level of 
femur; (D) transversal sections at the mid-diaphyseal level of femur. Values are expressed as 
mean  SEM. ***P<0.001 vs. C-OVX; +++P<0.01 vs. EB-OVX; #P<0.05, ##P<0.01, ###P<0.001 vs. 
SHAM (ANOVA followed by Newman–Keuls test). SHAM sham-operated controls receiving 
vehicle; C-OVX ovariectomized controls receiving vehicle; F-OVX ovariectomized treated with 
ferutinin; EB-OVX ovariectomized treated with estradiol benzoate. 
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Fig. 7. Preventing study. Mean values of histomorphometric normalized parameters, 
expressed as BV/TV (%/g) and Ct-B-Ar (mm2/g), in both trabecular and cortical bone of the 
four animal groups, after 60 days from ovariectomy. (A) Sagittal section of 4th lumbar 
vertebra; (B) transversal section of 5th lumbar vertebra; (C) sagittal section of the distal 
epiphyseal level of femur; (D) transversal section at the mid-diaphyseal level of femur. 
Values are expressed as mean ± SEM. ***P<0.001 vs. C-OVX; +P<0.05 vs. EB-OVX (ANOVA 
followed by Newman–Keuls test). SHAM sham-operated controls receiving vehicle; C-OVX 
ovariectomized controls receiving vehicle; F-OVX ovariectomized treated with ferutinin, EB-
OVX ovariectomized treated with estradiol benzoate. 
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3.2.2 Bone mass in recovering study protocol 
As regards both periods of time (30 and 60 days), the histological sections of vertebrae and 
femurs from SHAM and treated animal groups showed higher amount of trabecular bone 
(Figure 8A-B-C) with respect to C-OVX group, while the amount of cortical bone did not 
show differences among all groups (Fig. 8D). The histomorphometric analyses clearly 
showed the different results in trabecular and cortical bone: the amount of trabecular bone 
(Figures 9A-B-C and 10A-B-C) in F-OVX and EB-OVX animals are always higher with 
respect to C-OVX ones, although they do not reach the values of SHAM animals; as far as 
cortical bone (Figures 9D and 10D) is concerned, no statistically significant differences were 
found in bone area among all groups after both 30 and 60 days of treatments.  
 
 
Fig. 8. Recovering study. LM micrographs showing the bone histology from the four 
experimental animal groups after 30 days of treatment. (A) Sagittal sections of the 4th lumbar 
vertebra; (B) transversal sections of the 5th lumbar vertebra; (C) sagittal sections of the distal 
epiphysis of femur; (D) transversal sections at the mid-diaphyseal level of femur. (Figure by 
Ferretti et al., 2010). 
3.2.3 Uterine tissues 
Preliminary data, not yet published by the authors, concern also the side effects of the 
chronic treatment with ferutinin on the uterus of ovariectomized rats, particularly regarding 
weight, size, morphology and structure. The target was to compare ferutinin side effects 
with those elicited by estradiol benzoate treatment, both in preventing and recovering 
protocols. Although data are incomplete, ferutinin would seem to exert the same effect of 
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estrogen benzoate in increasing uterine weight not only in the preventing study but also in 
the recovering one. In particular, the morphological and morphometrical preliminary data 
suggest that ferutinin would act on the uterus in a manner similar to that of estradiol 
benzoate, stimulating endometrial hypertrophy. Moreover, the treatment with ferutinin is of 
particular interest because the apoptotic index in both preventing and recovering studies 
seems to be almost always higher in both luminal and glandular endometrial epithelia with 
respect to animal groups treated with estradiol benzoate. 
 
 
 
 
 
  
 
 
 
 
Fig. 9. Recovering study. Mean values of histomorphometric parameters, expressed as 
BV⁄TV (%) and Ct-B-Ar (mm2), in both trabecular and cortical bone of the all animal groups 
after 30 days of treatment. (A) Sagittal section of the 4th lumbar vertebra; (B) transversal 
section of the 5th lumbar vertebra; (C) sagittal section of the distal epiphysis of femur; (D) 
transversal section at the mid-diaphyseal level of femur. Values are expressed as mean ± 
SEM. *P< 0.05 vs. C-OVX; #P< 0.05, ###P< 0.001 vs. SHAM (ANOVA followed by Newman–
Keuls test). SHAM sham-operated controls receiving vehicle; C-OVX ovariectomized 
controls receiving vehicle; F-OVX ovariectomized treated with ferutinin; EB-OVX 
ovariectomized treated with estradiol benzoate.  
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Fig. 10. Recovering study. Mean values of histomorphometric parameters, expressed as 
BV⁄TV (%) and Ct-B-Ar (mm2), in both trabecular and cortical bone of the all animal groups 
after 60 days of treatment. (A) Sagittal section of the 4th lumbar vertebra; (B) transversal 
section of the 5th lumbar vertebra; (C) sagittal section of the distal epiphysis of femur;  
(D) transversal section at the mid-diaphyseal level of femur. Values are expressed as mean  
± SEM. *P< 0.05, **P< 0.01 vs. C-OVX; #P< 0.05, ##P< 0.01, ###P< 0.001 vs. SHAM (ANOVA 
followed by Newman–Keuls test). SHAM sham-operated controls receiving vehicle; C-OVX 
ovariectomized controls receiving vehicle; F-OVX ovariectomized treated with ferutinin;  
EB-OVX ovariectomized treated with estradiol benzoate. 
3.3 Serum biochemical analysis 
In preventing study protocol, serum level variations of magnesium, calcium and inorganic 
phosphorous among the groups were more evident after 30 days of treatment rather than 
after 60 days (Table 2), while in the recovering study protocol, no significant differences in 
serum levels were recorded (Table 3). As far as serum alkaline phosphatase is concerned, its 
levels in F-OVX animal groups were always higher with respect to all other groups both in 
preventive and recovering study protocols after 30 as well as 60 days of treatment.  
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TABLE 2 
Treatment 
group 
Mg (mg/dl) Ca (mg/dl) 
P inorganic 
(mg/dl) 
ALP (UI/l) 
3
0
 d
a
y
-
tr
e
a
tm
e
n
t SHAM 2.82±0.02 9.8±0.1 9.06±0.22 110.3±12.0 
C-OVX 2.94±0.09 10.2±0.05# 9.85±0.35 106.2±4.9 
F-OVX 2.74±0.04 9.6±0.1** ++ 7.59±0.21*** ## ++ 148.4±17.5 
EB-OVX 2.88±0.05 10.1±0.07 9.07±0.26 111.0±8.4 
6
0
 d
a
y
-
tr
e
a
tm
e
n
t SHAM 2.54±0.01 9.7±0.1 7.81±0.17 90.8±5.1 
C-OVX 2.52±0.05 9.7±0.2 7.76±0.34 102.6±4.2 
F-OVX 2.55±0.05 9.9±0.1 7.05±0.31 118.0±7.1++ 
EB-OVX 2.53±0.05 9.7±0.2 7.03±0.33 79.7±7.3 
Table 2. Preventing study. Effect of ferutinin/estradiol benzoate on serum biochemical 
values of ovariectomized rats treated for 30 and 60 days. All values are expressed as mean ± 
SEM. Anova followed by Newman-Keuls post test: **P<0.01, ***P<0.001 vs. C-OVX; ++P<0.01 
vs. EB-OVX; P<0.05, P<0.01 vs. SHAM. SHAM sham-operated  controls receiving vehicle; 
C-OVX ovariectomized controls  receiving vehicle; F-OVX ovariectomized treated with 
ferutinin; EB-OVX ovariectomized treated with estradiol benzoate. 
 
TABLE 3 
Treatment 
group 
Mg (mg/dl) Ca (mg/dl) 
P inorganic 
(mg/dl) 
ALP (UI/l) 
3
0
 d
a
y
-
tr
e
a
tm
e
n
t SHAM 2.43±0.06 10.6±0.01 6.29±0.43 103±13.65 
C-OVX 2.41±0.07 10.18±0.18 7.18±0.3 81.6±3.98 
F-OVX 2.43±0.04 10.56±0.1 6.09±0.22 144.6±15.4** #  ++ 
EB-OVX 2.48±0.05 10.52±0.1 6.57±0.25 75±12.5 
6
0
 d
a
y
-
tr
e
a
tm
e
n
t SHAM 2.57±0.06 10.25±0.16 7.52±0.46 89.5±9.24 
C-OVX 2.86±0.4 10.28±0.02 6.2±0.22# 90.2±8.61 
F-OVX 2.55±0.07 10.58±0.12 6.37±0.27# 109.2±7.19+ 
EB-OVX 2.47±0.04 10.58±0.14 6.02±0.17# 72.8±5.91 
Table 3. Recovering study. Effect of ferutinin/estradiol benzoate on serum biochemical 
values of ovariectomized rats (30 and 60 days of treatment). All values are expressed as 
mean ± SEM. Anova followed by Newman-Keuls post test: **P<0.01 vs. C-OVX; +P<0.05, 
++P<0.01 vs. EB-OVX; #P<0.05 vs. SHAM. SHAM sham-operated controls receiving vehicle; 
C-OVX ovariectomized controls  receiving vehicle; F-OVX ovariectomized treated with 
ferutinin; EB-OVX ovariectomized treated with estradiol benzoate. 
4. Discussion  
The results so far obtained have clearly suggested that ferutinin displays positive effects on 
bone mass both in preventing and in curative treatment of estrogen deficiency osteoporosis; 
more precisely, the observations have indicated that ferutinin seems to exert similar effects 
to estradiol benzoate in curative treatment (Ferretti et al., 2010), and even it seems to be 
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more effective, compared with estradiol benzoate, in preventing bone loss due to estrogen 
deficiency (Palumbo et al., 2009). It is to be underlined that, comparing the results from the 
two protocols, in curative study the values of bone mass of treated animals never reach 
those of  SHAM group; this is due to the fact that the treatment started after the occurrence 
of a severe osteoporosis (as a consequence of estrogen deficiency secondary to two months 
of ovariectomy). 
It is important to emphasise that one of the most important effects of skeletal diseases, like 
osteoporosis, is the progressive trabecular bone resorption that, in turn, implies enhanced 
bone fragility and, consequently, an increased frequency of fractures. According to the 
literature (Kalu, 1991; Wronski et al., 1987) ovariectomy in rats induces different effects on 
trabecular bone of the axial with respect to the appendicular skeleton, with more marked 
bone resorption taking place in the latter; for this reason, both vertebrae and femurs were 
investigated. Moreover, ovariectomy differently affects trabecular and cortical bone, since in 
OVX animals the bone mass loss observed in trabecular bone was not equally observed in 
cortical bone; in fact, the values of femur cortical bone areas are similar in OVX and SHAM 
groups. These data are in line with older ones showing an earlier started decrease in bone 
mass, more extensive in the spongiosa than in the compacta of rats fed a low-calcium diet 
(Lozupone & Favia, 1988). This fact is a consequence of the different pattern of  distribution 
of mechanical stresses acting on the two different bony architectures and it is probably 
related to the different metabolism of the various skeletal regions that, in turn, affect the 
bone turnover rate of the different skeletal regions, viz. metaphysis compared with 
diaphyses (Canè et al., 1982). Other authors have also shown that cortical bone is not very 
sensitive to bone loss due to ovariectomy standing the increased endosteal osteoblasts  (Jee 
et al., 1990; Liu & Kalu, 1990; Turner et al., 1987). All these considerations make the “Bone 
Organ” a sophisticated system in which metabolic and mechanical demands are actually 
sensed and integrated in answering both systemic and loading needs. 
As previously mentioned the authors wanted to evaluate whether the chronic 
administration of ferutinin, starting from the day after ovariectomy, is able to prevent 
estrogen deficiency effects similarly to HRT. The results obtained clearly showed that the 
phytoestrogen ferutinin displays positive effects in preventing osteoporosis due to estrogen 
deficiency; more precisely the observations suggest that ferutinin seems to be more effective 
in preventing bone loss compared with estradiol benzoate. Another positive aspect of 
ferutinin treatment is to prevent weight gain that typically occurs after ovariectomy. As 
above mentioned, ferutinin has been shown to interact with estrogen receptors (Appendino 
et al., 2002; Ikeda et al., 2002). While the majority of phytoestrogens have a higher relative 
binding affinity for ERǃ than ERǂ, ferutinin displays a higher affinity for ERǂ (IC50=33.1 nM) 
than for ERǃ (IC50=180.5 nM) (Ikeda et al., 2002). The different roles of specific estrogen 
receptors ERǂ and ERǃ on body weight regulation were recently investigated by Wegorzewska 
and co-workers (2008), using the ovariectomized rat model. OVX rats showed a significant 
increase in body weight, which was reversed by the daily treatment (for 21 days) with 
estradiol or PPT (propylpyrazoletriol, a selective ERǂ agonist), but not by the daily treatment 
with DPN (diarylpropionitrile, a ERǃ agonist); these results confirm the major role of ERǂ in 
regulating body weight, as it was previously suggested by other authors (Kraichely et al., 
2000; Stauffer et al., 2000) by using ER-specific knockout mice. 
Regarding the bone turnover-related serum levels, the recorded values of alkaline 
phosphatase (the most widely recognized biochemical marker for osteoblastic activity -
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Evans et al., 1990; Nian et al., 2006)  suggest that the process of osteogenesis should be 
triggered in F-OVX  group, because ALP value in F-OVX is higher with respect to the other 
groups. A positive effect on osteoblast activity in vitro by other phytoestrogens, like 
genistein, has already been published (Liao et al., 2007; Pan et al., 2005).  
As far as ferutinin side effects is concerned on the organs commonly targeted by estrogens, 
the apparent above cited antiapoptotic effect on endometrial epithelia is in line with 
observations previously recorded for genistein by other authors that administered such 
phytoestrogen to ovariectomized mice (Eason et al., 2005; Garcìa-Pérez et al., 2006). Since an 
increased risk of endometrial cancer due to excessive hypertrophy is one of the recognized 
prejudicial effects of estrogens, the phytoestrogen ferutinin, althought induces thickening of 
endometrium as well as estrogens, seems to increase the percentage of apoptotic epithelial 
cells, particularly the glandular ones. This effect might exert a protective role against uterine 
carcinoma.  
 
 
 
5. Conclusion 
On the light of the observations above reported on the effect of ferutinin in 
preventing/recovering severe osteoporosis secondary to ovariectomy in rats, the authors 
suggest to enumerate ferutinin among the osteoprotective substances. This fact acquires a 
more relevant importance in the light of recent tenable evidences, as above cited, reported 
from some authors concerning the absence of negative side effects by some phytoestrogens 
(particularly genistein, 8-prenylnaringenin, reveratrol and red clover extract) on the tropism 
of various organs commonly targeted by estrogens (Burdette et al., 2002; Duffy et al., 2007; 
Eason et al., 2005; Gallo et al., 2006; Garcia-Perez et al., 2006; Hümpel et al., 2005; Lian et al., 
2001; Limer & Speirs, 2004; Murray et al., 2003; Whitsett & Lamartiniere, 2006; Wu et al., 
2002). 
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In conclusion, the results here reported not only provide evidence that ferutinin can 
significantly prevent/recover ovariectomy-induced bone loss in rats, but also that it could 
protect against the onset of uterus cancer. Although the putative undesired estrogenic-like 
side effects on uterus of such  phytoestrogen have not yet been fully investigated, ferutinin 
could be an interesting safer alternative new candidate for HRT in treatment of post-
menopausal symptoms, since it seems to protect from bone loss induced by ovariectomy 
(Ferretti et al., 2010; Palumbo et al., 2009) and in part to mime the ovarian endocrine 
function during menopause.  The authors are aware that additional studies are required to 
characterize the mechanism by which ferutinin acts both in improving/resolving severe 
degrees of bone mass loss and in protecting from uterine cancer onset. 
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